HC Wainwright & Co. Maintains Buy on Karyopharm Therapeutics, Lowers Price Target to $8

Benzinga Newsdesk www.benzinga.com Negative 48.7%

Neg 48.7% Neu 0% Pos 0%

HC Wainwright & Co. analyst Robert Burns maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Buy and lowers the price target from $15 to $8.